Abstract: Parkinson’s disease (PD) is one of the most common neurodegenerative diseases, affecting individuals especially over 60 years of age. In the next three decades, more than 12 million people will suffer from PD worldwide (Rocca, 2018). The characteristic symptoms of PD begin as a movement disorder including bradykinesia, resting tremor, rigidity, and postural instability. Among these symptoms, bradykinesia is considered to be the major feature in diagnosing PD. At early stages, the motor symptoms of PD can be traced back to the loss of dopaminergic neurons of the substantia nigra (Armstrong and Okun, 2020). The other known neuropathological hallmark of PD is the intracellular inclusions containing the aggregates of a-synuclein (Armstrong and Okun, 2020). Nevertheless, consensus exists that the dysfunction of the interconnected neural networks plays a fundamental role in the presence of clinical symptoms given the anatomical and functional interactions within the brain. The current most prevalent clinical treatment involves substituting dopamine with medication and suppressing pathological neural activity via deep brain stimulation (DBS).